Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel

Comparison of Shear Stress-induced Thrombotic and Thrombolytic Effect d Thrombolytic Effect Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel in Patients With Acute Coronary Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03481257

Enrollment

Registered

2018-03-29

Start date

2017-04-12

Completion date

2018-02-04

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina

Brief summary

A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1 month. VerifyNow® and Global thrombosis test were performed at day 2 and 1 month after administration of study drugs. The investigators compared aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU), occlusion time (OT) which reflects shear stress-induced thrombotic activity, and lysis time (LT) which showed endogenous lytic activity between the two strategies at both time points.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who were diagnosed with acute coronary syndrome and underwent percutaneous coronary intervention

Exclusion criteria

* Patients administered with glycoprotein IIb/IIIa inhibitiors * Patients with atrial fibrillation * Patients with high risk of bleeding at the physician's discretion * Patients with renal impairment (estimated GFR \<30ml/min)

Design outcomes

Primary

Measure	Time frame	Description
Occlusion time	1 month	Global thrombosis test

Secondary

Measure	Time frame	Description
Lysis time	1 month	Global thrombosis test
P2Y12 reaction unit	Day 2 and 1 month	VerifyNow test
Aspirin reaction unit	Day 2 and 1 month	VerifyNow test
Occlusion time	Day 2	Global thrombosis test

Other

Measure	Time frame	Description
BARC bleeding	1 month	ARC definition
major adverse cardiovascular outcome	1 month	composites of cardiac death, myocardial infarction and target lesion revascularization

Countries

South Korea

Outcome results